NASDAQ: RIGL
Rigel Pharmaceuticals Inc Earnings Dates, Reports, Calls

Rigel Pharmaceuticals earnings were $367.0M for the trailing 12 months ending Dec 31, 2025, with 1,960.6% growth year over year. The latest RIGL earnings report on Dec 31, 2025 announced Q4 2025 earnings of $268.1M, up 860.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, RIGL reported annual earnings of $367.0M, with 1,999.1% growth.

RIGL past earnings growth

How has RIGL's earnings growth performed historically?

Company
1,960.61%
Industry
81.14%
Market
86.37%
RIGL's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
RIGL's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
RIGL's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

RIGL earnings history

Current Revenue
$294.3M
Current Earnings
$367.0M
Current Profit Margin
124.7%

RIGL Return on Equity

Current Company
240.8%
Current Industry
-9%
Current Market
29.5%
RIGL's Return on Equity (240.8%)... subscribe to Premium to read more.
High Return on Equity Performance

RIGL Return on Assets

Current Company
128.9%
Current Industry
-6.1%
RIGL is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when RIGL announces earnings.

RIGL Return on Capital Employed

Current Company
31.17%
Current Industry
-0.4%
RIGL has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RIGL vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
RIGL$131.56M$367.02M+1,960.61%$20.40
ENGN-$118.31M-$122.44MN/A-$2.25
FDMT-$201.75M-$209.18MN/A-$3.75
CTNM-$58.58M-$59.98MN/A-$2.17
TRDA-$138.73M-$143.75MN/A-$3.47

Rigel Pharmaceuticals Earnings Reports & History FAQ

What were Rigel Pharmaceuticals's earnings last quarter?

Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q4 2025 earnings per share (EPS) of $14.88, up 1,737.04% year over year. Total RIGL earnings for the quarter were $268.07 million. In the same quarter last year, Rigel Pharmaceuticals's earnings per share (EPS) was $0.81.

If you're new to stock investing, here's how to buy Rigel Pharmaceuticals stock.

Is Rigel Pharmaceuticals profitable or losing money?

As of the last Rigel Pharmaceuticals earnings report, Rigel Pharmaceuticals is currently profitable. Rigel Pharmaceuticals's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $367.02 million, a 1,999.08% increase year over year.

What was RIGL's earnings growth in the past year?

As of Rigel Pharmaceuticals's earnings date in Q1 2026, Rigel Pharmaceuticals's earnings has grown 1,960.61% year over year. This is 1,879.47 percentage points higher than the US Biotechnology industry earnings growth rate of 81.14%. RIGL earnings in the past year totalled $367.02 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.